News for Longeveron Inc. (LGVN)

Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. ( LGVN), a clinical

Roth MKM is organizing a group dinner meeting in Boston on June 16. This gathering aims to provide an ideal platform for investors to gain insights and make inf

MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. ( LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies f

Longeveron Inc. (LGVN) to participate in H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. CEO Wa'el Hashad will present a pre-recorded c

Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapyStem cell therapy laromestorcel being evaluated as potential treat

Selected as Top 40 Semifinalist in the XPRIZE Healthspan competition, receiving a $250,000 Milestone 1 Award Positive initial results across 5 clinical

Longeveron Inc. (NASDAQ:LGVN) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ETCompany ParticipantsDerek Cole - Investor Relations-Advisory...

Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximatel

**media[612779]**

MIAMI, April 22, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. ( LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies

Operator: Good day, and welcome to the Longeveron 2024 and Full Year Financial Results Conference Call. At this time all participants are in a listen-only mode.

Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Conference Call February 28, 2025 4:30 PM ETCompany ParticipantsDerek Cole - IR, Advisory SolutionsWa'el...

Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-Bâ„¢ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orpha

**media[553860,553861]**

Longeveron Inc (LGVN) is set to release its Q4 2024 earnings on Feb 28, 2025. The consensus estimate for Q4 2024 revenue is $0.63 million, and the earnings are

**media[546622]**

**media[544182]**

MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Co

Cellular therapy Lomecel-Bâ„¢ has been granted an International Non-proprietary Name (INN) of ”œlaromestrocel” on the INN List issued by the World Health Org